Fundraising FoxNovalis LifeSciences — 2022 Investments
6 investments dated 2022 · listed companies and verified rows first · show all
Animol is a biopharmaceutical company developing a proprietary pipeline of novel veterinary small-molecule drugs for both companion and farm animals, targeting areas from anti-parasitics to chronic diseases.
AgTechAI & Machine LearningBiotechDeep TechHealthtechBoston, US
Andrew Calabrese(Scientific Co-Founder)inAndrew Calabrese, Ph.D.(Scientific Co-Founder)Douglas E. Hutchens(CSO)inLogan Andrews(Head of Program Management)inPhilip Austin(Managing Partner, Anterra Capital; co-founder of Animol)inAndrew Plant(Executive Officer, Director)in
Board seatMarijn Dekkers· per SEC Form D
Co-investorsAnterra CapitalDYDX Capital
Early commercial stage company selling a real-time cell analyzer to pharma companies.
BiotechCharlottesville, US
Sean Hart(Executive Officer, Director)inRenee Hart(Executive Officer, Director)Robert Heiser(Director)Pete Buzy(Director)Dennis Walczewski(Director)Paul Meister(Director)
Board seatPaul Meister· per SEC Form D · $9.3M raise · filed Mar 2022
Co-investorsAsahi Kasei Corporate Venture Capital
Ori develops expandable-unit technology for multifamily real estate, enabling hotel-to-housing conversions and ground-up developments that increase unit density while maintaining livability.
Construction TechHardwareImpact & Social GoodPropTech
Hasier Larrea(Founder)
Co-investorsIngka InvestmentsPresidio VenturesThe E14 FundAmadeus Capital PartnersDelin VenturesEpisode1+4 more
ORI provides an integrated business planning platform for supply chain professionals, combining demand planning, S&OP, S&OE, data analytics, and long-term planning in one tool.
AI & Machine LearningLogistics & Supply ChainSaaS
Brant Slade(Founder)in
Co-investorsKickstartAmadeus Capital PartnersDelin VenturesKhosla VenturesNorthpond VenturesOctopus Ventures+2 more
Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.
Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical Devices
Co-investorsAmadeus Capital PartnersKindred CapitalOctopus VenturesDelin VenturesKindredNorthpond Ventures+1 more
HealthtechCambridge, US
Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPIllumina VenturesCatalio Capital ManagementGood VenturesGV (Google Ventures)Northpond Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.